CalciMedica (CALC) Stock Price, News & Analysis

Company Overview

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

Key Stats

• Today's Range: $2.76 to $2.89
• 50-Day Range: $2.70 to $4.80
• 52-Week Range: $2.05 to $8.38
• Volume: 68,617 shs
• Average Volume: 39,432 shs
• Market Capitalization: $37.21 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $19.33
• Consensus Rating: Buy

CalciMedica Stock Analysis - MarketRank™

CalciMedica scored higher than 59% of companies evaluated by MarketBeat, and ranked 433rd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

CalciMedica has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

CalciMedica has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for CalciMedica are expected to decrease in the coming year, from ($2.21) to ($2.24) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CalciMedica is -2.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CalciMedica is -2.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

CalciMedica has a P/B Ratio of 1.94. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.80% of the float of CalciMedica has been sold short.

Short Interest Ratio / Days to Cover

CalciMedica has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CalciMedica has recently decreased by 35.52%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CalciMedica does not currently pay a dividend.

Dividend Growth

CalciMedica does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.80% of the float of CalciMedica has been sold short.

Short Interest Ratio / Days to Cover

CalciMedica has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CalciMedica has recently decreased by 35.52%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for CalciMedica this week, compared to 1 article on an average week.

Search Interest

5 people have searched for CALC on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.

MarketBeat Follows

2 people have added CalciMedica to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, CalciMedica insiders have bought more of their company's stock than they have sold. Specifically, they have bought $942,510.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

41.55% of the stock of CalciMedica is held by insiders. A high percentage of insider ownership can be a sign of company health.

CALC Stock Analysis - Frequently Asked Questions

How have CALC shares performed this year?

CalciMedica's stock was trading at $2.86 at the beginning of the year. Since then, CALC shares have decreased by 3.5% and is now trading at $2.76.
View the best growth stocks for 2024 here.

Who are CalciMedica's major shareholders?

CalciMedica's top institutional shareholders include BML Capital Management LLC (1.43%), Geode Capital Management LLC (0.62%), Atria Investments Inc (0.25%) and PVG Asset Management Corp (0.11%). Insiders that own company stock include Sanderling Venture Partners Vi, Robert N Wilson, Eric W Roberts and A Rachel Leheny.
View institutional ownership trends.

How do I buy shares of CalciMedica?

Shares of CALC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of CalciMedica own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CalciMedica investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), NIO (NIO), Bakkt (BKKT) and Castor Maritime (CTRM).

Company Calendar

• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CALC
• CUSIP: N/A
• CIK: 1534133
• Web: www.graybug.vision
• Phone: 858-952-5500
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $19.33
• High Stock Price Target: $22.00
• Low Stock Price Target: $16.00
• Potential Upside/Downside: +600.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.08)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-34,360,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -164.24%
• Return on Assets: -103.53%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.15
• Quick Ratio: 4.15

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.42 per share
• Price / Book: 1.94

Miscellaneous

• Outstanding Shares: 13,482,000
• Free Float: 7,880,000
• Market Cap: $37.21 million
• Optionable: No Data
• Beta: 1.25